Mucormycosis of the intestine: A rare complication in Crohn's disease

Gastroenterology and Hepatology

Volumn 8, Issue 2, 2012, Pages 137-140

  Morton, Jordan ^a   Nguyen, Vincent ^a   Ali, Tauseef ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; CORTICOSTEROID; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; POSACONAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ACID FAST BACTERIUM; ARTICLE; CECOSTOMY; CECUM; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE SEVERITY; DRUG MEGADOSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; ILEOSTOMY; INTESTINE INFECTION; INTESTINE PERFORATION; LAPAROTOMY; LEUKOCYTE COUNT; MUCORMYCOSIS; NEUTROPHIL COUNT; TREATMENT DURATION;

EID: 84856876048     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep. 2007;9:435-440. (Pubitemid 350081423)
2. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-569. (Pubitemid 40995116)
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653. (Pubitemid 41170352)
4. Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. Am J Roentgenol. 1985;145:739-741. (Pubitemid 16216506)
5. Lawrence IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor- alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25:1732-1738.
6. D'Haens G, Colombel JF, Hommes DW, et al. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology. 2008;34(suppl):A-140.
7. Korzenik JR. Is Crohn's disease due to defective immunity? Gut. 2007;56:2-5. (Pubitemid 46044879)
8. Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? Swiss Med Wkly. 2009;139:527-534.
9. Wall GC, Leman BI. Mucormycosis in a Crohn's disease patient treated with infliximab. Digestion. 2009;80:182-184.
10. Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci. 2007;52:2078-2081. (Pubitemid 47246500)
11. Hunter AJ, Bryant RE. Abdominal wall mucormycosis successfully treated with amphotericin and intraconazole. J Infect. 2002;44:203-204. (Pubitemid 36104779)
12. Hyvernat H, Dunais B, Burel-Vandenbos F, Guidicelli S, Bernardin G, Gari-Toussaint M. Fatal peritonitis caused by Rhizopus microsporus. Med Mycol. 2010;48:1096-1098.
13. Gubarev N, Separovic J, Gasparovic V, Jelic I. Successful treatment of mucormycosis endocarditis complicated by pulmonary involvement. Thorac Cardiovasc Surg. 2007;55:257-258. (Pubitemid 47356215)
14. Ibañez R, Serrano-Heranz R, Sánchez-Zaballos I, Carbonero P, López G. Disseminated mucormycosis due to Absidia corymbifera in a patient with inflammatory bowel disease. Clin Microbiol Infect. 1997;3:268-270. (Pubitemid 27202323)
15. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45:667-671. (Pubitemid 24094476)